Drug Profile
Research programme: androgen receptor antagonists - ESSA Pharma
Alternative Names: ANITAC™ degraders; ANITen bAsed Chimera degraders; Anitens; EPI-001Latest Information Update: 13 Apr 2022
Price :
$50
*
At a glance
- Originator ESSA Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 08 Apr 2022 Preclinical pharmacodynamic data in castration-resistant Prostate cancer presented at the American Association for Cancer Research (AACR-2022)
- 08 Mar 2022 Preclinical trials in Prostate cancer in Canada (PO)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Prostate-cancer in Canada (Intratumoural)